用Janus激酶抑制剂治疗扁平苔藓毛发角化病。 - Suppr

Suppr

超能文献

Treatment of lichen planopilaris with Janus kinase inhibitors.

作者信息

Gonzalez Matheus Gabriela A, Khosrotehrani Kiarash

机构信息

Queensland Institute of Dermatology, Brisbane, Queensland, Australia.

出版信息

Australas J Dermatol. 2024 Jun;65(4):381-383. doi: 10.1111/ajd.14240. Epub 2024 Feb 29.

DOI:10.1111/ajd.14240

PMID:38421900

Abstract

摘要

相似文献

Treatment of lichen planopilaris with Janus kinase inhibitors.

Australas J Dermatol. 2024 Jun;65(4):381-383. doi: 10.1111/ajd.14240. Epub 2024 Feb 29.

Treatment of severe lichen planus with the JAK inhibitor tofacitinib.

J Allergy Clin Immunol. 2020 Jun;145(6):1708-1710.e2. doi: 10.1016/j.jaci.2020.01.031. Epub 2020 Feb 1.

Review of the use of Janus kinase inhibitors in the treatment of scarring alopecia.

Int J Dermatol. 2024 Jun;63(6):e105-e110. doi: 10.1111/ijd.17153. Epub 2024 Apr 3.

Tofacitinib as Treatment for Nail Lichen Planus Associated With Alopecia Universalis.

JAMA Dermatol. 2021 Mar 1;157(3):352-353. doi: 10.1001/jamadermatol.2020.4555.

Tofacitinib in the treatment of lichen planopilaris: A retrospective review.

J Am Acad Dermatol. 2020 Nov;83(5):1487-1489. doi: 10.1016/j.jaad.2020.05.104. Epub 2020 May 29.

Janus-kinase inhibitors in dermatology: A review of their use in psoriasis, vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis and graft-versus-host disease.

Indian J Dermatol Venereol Leprol. 2023;90(1):30-40. doi: 10.25259/IJDVL_15_2023.

Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals.

Ann Rheum Dis. 2021 Sep;80(9):1245-1246. doi: 10.1136/annrheumdis-2021-220049. Epub 2021 Jun 7.

Successful treatment of resistant lichen planopilaris with topical tofacitinib monotherapy.

Ann Dermatol Venereol. 2024 Sep;151(3):103303. doi: 10.1016/j.annder.2024.103303. Epub 2024 Aug 17.

Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib.

J Invest Dermatol. 2017 Apr;137(4):951-954. doi: 10.1016/j.jid.2016.10.044. Epub 2016 Nov 22.

Tofacitinib for the treatment of lichen planopilaris: A case series.

Dermatol Ther. 2018 Nov;31(6):e12656. doi: 10.1111/dth.12656. Epub 2018 Sep 27.

引用本文的文献

Unravelling the transcriptomic landscape of primary lymphocytic scarring alopecias: systematic review and meta-analysis.

Front Immunol. 2025 Aug 11;16:1651019. doi: 10.3389/fimmu.2025.1651019. eCollection 2025.

Use of JAK Inhibitors in Lichen Planus: An Update.

Medicina (Kaunas). 2025 Jun 8;61(6):1056. doi: 10.3390/medicina61061056.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Treatment of lichen planopilaris with Janus kinase inhibitors.

作者信息

Gonzalez Matheus Gabriela A, Khosrotehrani Kiarash

机构信息

Queensland Institute of Dermatology, Brisbane, Queensland, Australia.

出版信息

Australas J Dermatol. 2024 Jun;65(4):381-383. doi: 10.1111/ajd.14240. Epub 2024 Feb 29.

DOI:10.1111/ajd.14240

PMID:38421900

Abstract

摘要

相似文献

Treatment of lichen planopilaris with Janus kinase inhibitors.

Australas J Dermatol. 2024 Jun;65(4):381-383. doi: 10.1111/ajd.14240. Epub 2024 Feb 29.

Treatment of severe lichen planus with the JAK inhibitor tofacitinib.

J Allergy Clin Immunol. 2020 Jun;145(6):1708-1710.e2. doi: 10.1016/j.jaci.2020.01.031. Epub 2020 Feb 1.

Review of the use of Janus kinase inhibitors in the treatment of scarring alopecia.

Int J Dermatol. 2024 Jun;63(6):e105-e110. doi: 10.1111/ijd.17153. Epub 2024 Apr 3.

Tofacitinib as Treatment for Nail Lichen Planus Associated With Alopecia Universalis.

JAMA Dermatol. 2021 Mar 1;157(3):352-353. doi: 10.1001/jamadermatol.2020.4555.

Tofacitinib in the treatment of lichen planopilaris: A retrospective review.

J Am Acad Dermatol. 2020 Nov;83(5):1487-1489. doi: 10.1016/j.jaad.2020.05.104. Epub 2020 May 29.

Indian J Dermatol Venereol Leprol. 2023;90(1):30-40. doi: 10.25259/IJDVL_15_2023.

Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals.

Ann Rheum Dis. 2021 Sep;80(9):1245-1246. doi: 10.1136/annrheumdis-2021-220049. Epub 2021 Jun 7.

Successful treatment of resistant lichen planopilaris with topical tofacitinib monotherapy.

Ann Dermatol Venereol. 2024 Sep;151(3):103303. doi: 10.1016/j.annder.2024.103303. Epub 2024 Aug 17.

Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib.

J Invest Dermatol. 2017 Apr;137(4):951-954. doi: 10.1016/j.jid.2016.10.044. Epub 2016 Nov 22.

Tofacitinib for the treatment of lichen planopilaris: A case series.

Dermatol Ther. 2018 Nov;31(6):e12656. doi: 10.1111/dth.12656. Epub 2018 Sep 27.

引用本文的文献

Unravelling the transcriptomic landscape of primary lymphocytic scarring alopecias: systematic review and meta-analysis.

Front Immunol. 2025 Aug 11;16:1651019. doi: 10.3389/fimmu.2025.1651019. eCollection 2025.

Use of JAK Inhibitors in Lichen Planus: An Update.

Medicina (Kaunas). 2025 Jun 8;61(6):1056. doi: 10.3390/medicina61061056.